Transcend Medical develops the CyPass Micro‑Stent, a micro‑invasive glaucoma implant designed to reduce intraocular pressure by enhancing aqueous outflow to the suprachoroidal space. The CyPass Micro‑Stent has received the CE Mark and is currently for investigational use in the U.S. The company closed a $22M Series C to fund its clinical and regulatory efforts. Transcend intends to use the proceeds to complete the U.S.-based, randomized, controlled COMPASS pivotal trial evaluating the CyPass Micro‑Stent, with the trial scheduled to complete in the second quarter of 2015. The company is led by President and CEO Brian Walsh. Previously, the company held a second close of a $51M Series B in 2011. Transcend Medical is a Menlo Park, Calif.-based ophthalmic device company focused on minimally invasive glaucoma therapies. Its core product is the CyPass Micro-Stent, a tiny implant placed in the eye through a minimally invasive surgical procedure designed to reduce or eliminate the need for glaucoma medications while providing continuous control of intraocular pressure. The company held the second close of its Series B financing, bringing the total raised in the round to $51M. Investors in the round include new backer Investor Growth Capital and existing shareholders Canaan Partners, Finistere Ventures, HLM Venture Partners, Kaiser Permanente Ventures, Latterell Venture Partners, Morgenthaler Ventures, Split Rock Partners and Technology Partners. Transcend plans to use the capital to develop additional infrastructure and resources for a U.S. study of its micro-stent technology. Led by President and CEO Brian Walsh, the company spun out from ForSight Labs, LLC, an incubator focused on ophthalmic innovations.

Total raised

$73M

Funding rounds

2

Latest round

Series C

Latest activity

Apr 2014